[EN] ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS<br/>[FR] ACIDES ALKYLBORONIQUES EN TANT QU'INHIBITEURS D'ARGINASE
申请人:GUANGDONG NEWOPP BIOPHARMACEUTICALS CO LTD
公开号:WO2020160707A1
公开(公告)日:2020-08-13
Provided are alkylboronic acids as arginase inhibitors represented by formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof and a pharmaceutical composition comprising said compounds.
[EN] HETEROCYCLIC COMPOUNDS AS ARGINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE L'ARGINASE
申请人:GUANGDONG NEWOPP BIOPHARMACEUTICALS CO LTD
公开号:WO2019120296A1
公开(公告)日:2019-06-27
The present invention relates to heterocyclic compounds as arginase inhibitors, in particular to a compound represented by Formula (I), or a pharmaceutically acceptable salt, stereoisomer or tautomer, or prodrug thereof and a pharmaceutical composition comprising said compound.
[EN] DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSÉS CONTENANT UN DI-FLUORO EN TANT QU'INHIBITEURS DE CYSTÉINE PROTÉASE
申请人:VIROBAY INC
公开号:WO2009123623A1
公开(公告)日:2009-10-08
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
An original synthesis of trans-1,2-diaminocyclobutane
作者:Fabrice Vergne、Karolin Partogyan、David J. Aitken、Henri-Philippe Husson
DOI:10.1016/0040-4020(95)01091-2
日期:1996.2
A new synthesis of trans-1,2-diaminocyclobutane 1 is described, in which the key feature is the novel stereoselective borane-induced reductive ring-expansion reaction of the cyclopropane-iminonitrile 2 to give the cyclobutane 4. This latter intermediate was also used to prepare a trans-fused rigid analogue of moclobemide.
Haloalkyl containing compounds as cysteine protease inhibitors
申请人:Link O. John
公开号:US20050182096A1
公开(公告)日:2005-08-18
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.